Comparison of 10-Day Course of Triple Therapy Versus 14-Day Course for Eradication of Helicobacter pylori Infection in an Indonesian Population: Double-Blinded Randomized Clinical Trial

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: The aim of this study was to compare the effectiveness of 10-day course of triple therapy versus a 14-day course in the treatment of H.pylori infection in an Indonesian population. METHODS: A double-blinded randomized clinical trial was included patients, Indonesian population, with H.pylori infection conducted in Cipto Mangunkusumo Hospital, Jakarta; Cilincing District General Hospital, Jakarta; and West Nusa Tenggara General Hospital, Mataram, during October 2016 - April 2017. Patients were randomized to be given triple therapy as Rabeprazole 20 mg, Amoxicillin 1,000 mg, and Clarithromycin 500 mg twice daily, for 14 days or 10 days plus 4 days placebo. Eradication was evaluated with UBT at least 4 weeks after completion the therapy. RESULTS: A total of 75 patients (38 in the 14-day group and 37 in the 10-day group) were included to the study. In the intention-to-threat analysis, eradication rate was 67.6% (95% CI. 52.5%-82.6%) for the 10-day group versus 86.8% (95% CI. 76.0%-97.5%) for the 14-day group (p = 0.046), whereas per protocol analysis obtained 73.5% (95% CI. 58.6%-88.3%) for the 10-day versus 91.9% (95% CI. 84.1%-99.6%) in the 14-day group (p = 0.039). Adverse events were not significantly different between the two groups. CONCLUSION: A 14-day course was more effective than 10-day course of triple therapy as first-line for eradication of H.pylori infection in an Indonesian population.

Original languageEnglish
Pages (from-to)19-24
Number of pages6
JournalAsian Pacific journal of cancer prevention : APJCP
Volume21
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020

Fingerprint

Helicobacter Infections
Helicobacter pylori
Randomized Controlled Trials
Pylorus
Population
General Hospitals
Infection
Rabeprazole
Therapeutics
Clarithromycin
District Hospitals
Amoxicillin
Placebos

Keywords

  • Duration
  • eradication
  • Helicobacter pylori
  • Indonesian population
  • Triple therapy

Cite this

@article{f83a55a4e5084b63841c5046bc5f4267,
title = "Comparison of 10-Day Course of Triple Therapy Versus 14-Day Course for Eradication of Helicobacter pylori Infection in an Indonesian Population: Double-Blinded Randomized Clinical Trial",
abstract = "OBJECTIVE: The aim of this study was to compare the effectiveness of 10-day course of triple therapy versus a 14-day course in the treatment of H.pylori infection in an Indonesian population. METHODS: A double-blinded randomized clinical trial was included patients, Indonesian population, with H.pylori infection conducted in Cipto Mangunkusumo Hospital, Jakarta; Cilincing District General Hospital, Jakarta; and West Nusa Tenggara General Hospital, Mataram, during October 2016 - April 2017. Patients were randomized to be given triple therapy as Rabeprazole 20 mg, Amoxicillin 1,000 mg, and Clarithromycin 500 mg twice daily, for 14 days or 10 days plus 4 days placebo. Eradication was evaluated with UBT at least 4 weeks after completion the therapy. RESULTS: A total of 75 patients (38 in the 14-day group and 37 in the 10-day group) were included to the study. In the intention-to-threat analysis, eradication rate was 67.6{\%} (95{\%} CI. 52.5{\%}-82.6{\%}) for the 10-day group versus 86.8{\%} (95{\%} CI. 76.0{\%}-97.5{\%}) for the 14-day group (p = 0.046), whereas per protocol analysis obtained 73.5{\%} (95{\%} CI. 58.6{\%}-88.3{\%}) for the 10-day versus 91.9{\%} (95{\%} CI. 84.1{\%}-99.6{\%}) in the 14-day group (p = 0.039). Adverse events were not significantly different between the two groups. CONCLUSION: A 14-day course was more effective than 10-day course of triple therapy as first-line for eradication of H.pylori infection in an Indonesian population.",
keywords = "Duration, eradication, Helicobacter pylori, Indonesian population, Triple therapy",
author = "Ryan Herardi and Syam, {Ari Fahrial} and Marcellus Simadibrata and Siti Setiati and Nikko Darnindro and Murdani Abdullah and Dadang Makmun",
year = "2020",
month = "1",
day = "1",
doi = "10.31557/APJCP.2020.21.1.19",
language = "English",
volume = "21",
pages = "19--24",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "1",

}

TY - JOUR

T1 - Comparison of 10-Day Course of Triple Therapy Versus 14-Day Course for Eradication of Helicobacter pylori Infection in an Indonesian Population

T2 - Double-Blinded Randomized Clinical Trial

AU - Herardi, Ryan

AU - Syam, Ari Fahrial

AU - Simadibrata, Marcellus

AU - Setiati, Siti

AU - Darnindro, Nikko

AU - Abdullah, Murdani

AU - Makmun, Dadang

PY - 2020/1/1

Y1 - 2020/1/1

N2 - OBJECTIVE: The aim of this study was to compare the effectiveness of 10-day course of triple therapy versus a 14-day course in the treatment of H.pylori infection in an Indonesian population. METHODS: A double-blinded randomized clinical trial was included patients, Indonesian population, with H.pylori infection conducted in Cipto Mangunkusumo Hospital, Jakarta; Cilincing District General Hospital, Jakarta; and West Nusa Tenggara General Hospital, Mataram, during October 2016 - April 2017. Patients were randomized to be given triple therapy as Rabeprazole 20 mg, Amoxicillin 1,000 mg, and Clarithromycin 500 mg twice daily, for 14 days or 10 days plus 4 days placebo. Eradication was evaluated with UBT at least 4 weeks after completion the therapy. RESULTS: A total of 75 patients (38 in the 14-day group and 37 in the 10-day group) were included to the study. In the intention-to-threat analysis, eradication rate was 67.6% (95% CI. 52.5%-82.6%) for the 10-day group versus 86.8% (95% CI. 76.0%-97.5%) for the 14-day group (p = 0.046), whereas per protocol analysis obtained 73.5% (95% CI. 58.6%-88.3%) for the 10-day versus 91.9% (95% CI. 84.1%-99.6%) in the 14-day group (p = 0.039). Adverse events were not significantly different between the two groups. CONCLUSION: A 14-day course was more effective than 10-day course of triple therapy as first-line for eradication of H.pylori infection in an Indonesian population.

AB - OBJECTIVE: The aim of this study was to compare the effectiveness of 10-day course of triple therapy versus a 14-day course in the treatment of H.pylori infection in an Indonesian population. METHODS: A double-blinded randomized clinical trial was included patients, Indonesian population, with H.pylori infection conducted in Cipto Mangunkusumo Hospital, Jakarta; Cilincing District General Hospital, Jakarta; and West Nusa Tenggara General Hospital, Mataram, during October 2016 - April 2017. Patients were randomized to be given triple therapy as Rabeprazole 20 mg, Amoxicillin 1,000 mg, and Clarithromycin 500 mg twice daily, for 14 days or 10 days plus 4 days placebo. Eradication was evaluated with UBT at least 4 weeks after completion the therapy. RESULTS: A total of 75 patients (38 in the 14-day group and 37 in the 10-day group) were included to the study. In the intention-to-threat analysis, eradication rate was 67.6% (95% CI. 52.5%-82.6%) for the 10-day group versus 86.8% (95% CI. 76.0%-97.5%) for the 14-day group (p = 0.046), whereas per protocol analysis obtained 73.5% (95% CI. 58.6%-88.3%) for the 10-day versus 91.9% (95% CI. 84.1%-99.6%) in the 14-day group (p = 0.039). Adverse events were not significantly different between the two groups. CONCLUSION: A 14-day course was more effective than 10-day course of triple therapy as first-line for eradication of H.pylori infection in an Indonesian population.

KW - Duration

KW - eradication

KW - Helicobacter pylori

KW - Indonesian population

KW - Triple therapy

UR - http://www.scopus.com/inward/record.url?scp=85078342241&partnerID=8YFLogxK

U2 - 10.31557/APJCP.2020.21.1.19

DO - 10.31557/APJCP.2020.21.1.19

M3 - Article

C2 - 31983158

AN - SCOPUS:85078342241

VL - 21

SP - 19

EP - 24

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 1

ER -